A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2019-08-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of baricitinib as
monotherapy in participants with moderate to severe atopic dermatitis.